Maymetsi

Metformin Hydrochloride and Sitagliptin, the active ingredient in Maymetsi, is a Biguanide and DPP‑4 inhibitor combination presented as a combination tablet for oral use. It treats type 2 diabetes mellitus in adults. GNH USA supplies Maymetsi as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Maymetsi, a combination of metformin and sitagliptin, is indicated for management of type 2 diabetes mellitus.

Type 2 diabetes mellitus: improves overall glycaemic control when used with diet and exercise. Inadequate control on metformin alone: provides additional glucose‑lowering effect. Combination therapy with other antidiabetics: can be added to sulfonylureas, insulin or thiazolidinediones for enhanced control.

Maymetsi may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Nausea or upset stomach. - Diarrhoea or loose stools. - Abdominal discomfort or flatulence. - Headache or mild dizziness.

Serious or Rare Side Effects: - Lactic acidosis, a potentially life‑threatening metabolic disturbance. - Severe hypoglycaemia, especially when combined with insulin or sulfonylureas. - Acute pancreatitis presenting with abdominal pain and elevated enzymes. - Allergic reactions such as rash, angio‑edema or anaphylaxis.

Before initiating Maymetsi, several safety considerations should be reviewed. - Renal function assessment: avoid or adjust dose in patients with impaired renal clearance. - Hepatic impairment: monitor liver enzymes and avoid in severe liver disease. - Risk of lactic acidosis: contraindicated in conditions predisposing to hypoxia. - Concomitant hypoglycaemic agents: monitor blood glucose to prevent severe lows. - Contraindicated in severe renal impairment (eGFR <30 mL/min/1.73 m²). - Store at room temperature: keep in the original container, protect from moisture and heat.

Maymetsi can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Intravenous iodinated contrast agents: may precipitate metformin‑associated lactic acidosis. - Strong CYP3A4 inhibitors (e.g., ketoconazole): increase sitagliptin exposure. - Insulin or sulfonylureas: heightened risk of hypoglycaemia. - Cimetidine: raises sitagliptin plasma levels.

Moderate Interactions (Monitor Closely): - Diuretics: may affect renal clearance of metformin. - ACE inhibitors or ARBs: combined effect on renal function. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): potential impact on kidney function. - Alcohol: can increase risk of lactic acidosis.